O
688238
vs
S
Shanghai Composite
Over the past 12 months, Obio Technology Shanghai Corp Ltd has outperformed Shanghai Composite, delivering a return of +35% compared to the Shanghai Composite's +24% growth.
Stocks Performance
688238 vs Shanghai Composite
Performance Gap
688238 vs Shanghai Composite
Performance By Year
688238 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Obio Technology Shanghai Corp Ltd
Glance View
Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.
